MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Cost of Revenue 2011-2026 | ADMP
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.19 M | 6.87 M | 6.33 M | 15.5 M | 9.8 M | 7.42 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.5 M | 6.19 M | 8.68 M |
Quarterly Cost of Revenue Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 338 K | 1.79 M | - | 1.65 M | 689 K | 1.46 M | - | 1.57 M | 1.8 M | 1.85 M | - | 1.41 M | 4.68 M | 3.69 M | - | 3.99 M | 3.67 M | 3.63 M | - | 2.3 M | 2.39 M | 2.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.68 M | 338 K | 2.29 M |
Cost of Revenue of other stocks in the Drug manufacturers industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
5.82 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
8.98 M | - | 10.11 % | $ 58.2 M | USA |
 |
Assertio Holdings
ASRT
|
35.4 M | $ 18.41 | -1.02 % | $ 118 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
26.8 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
3.43 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
1.72 M | - | - | $ 50.1 M | USA |
 |
Endo International plc
ENDP
|
946 M | - | - | $ 28.9 M |  Irlanda |
 |
Alimera Sciences
ALIM
|
10.8 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
76.1 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
15.3 M | - | - | $ 2.06 B |  France |
 |
Harrow Health
HROW
|
67.9 M | $ 36.73 | 3.67 % | $ 1.35 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
6.59 M | $ 3.14 | 2.28 % | $ 44.1 M | USA |
 |
Jupiter Wellness
JUPW
|
2.69 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
294 M | - | 1.15 % | $ 7.11 M | USA |
 |
Canopy Growth Corporation
CGC
|
189 M | $ 1.04 | 4.83 % | $ 112 M |  Canada |
 |
Organogenesis Holdings
ORGO
|
116 M | $ 2.39 | 5.75 % | $ 315 M | USA |
 |
Pacira BioSciences
PCRX
|
170 M | $ 23.25 | 3.2 % | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
849 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
52 M | - | - | $ 5.07 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
85.5 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
100 M | $ 4.09 | 0.25 % | $ 264 M | USA |
 |
Emergent BioSolutions
EBS
|
705 M | $ 8.39 | 6.88 % | $ 430 M | USA |
 |
OrganiGram Holdings
OGI
|
104 M | $ 1.39 | 1.46 % | $ 402 M | Canada |
 |
Radius Health
RDUS
|
18.4 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
76.5 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
4.04 K | $ 7.01 | 3.85 % | $ 277 M | USA |
 |
Sundial Growers
SNDL
|
56.1 M | $ 1.36 | 3.82 % | $ 3.37 M | Canada |
 |
SCYNEXIS
SCYX
|
15.4 M | $ 1.0 | 3.87 % | $ 49.9 M | USA |
 |
OptiNose
OPTN
|
8.63 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
4.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
8.82 M | $ 2.29 | 3.62 % | $ 2.84 M | USA |
 |
Tilray
TLRY
|
480 M | $ 6.75 | 4.49 % | $ 4.17 B | Canada |
 |
Veru
VERU
|
11 M | $ 2.55 | 2.82 % | $ 344 M | USA |
 |
Viatris
VTRS
|
8.99 B | $ 13.57 | 3.12 % | $ 16.3 B | USA |
 |
cbdMD
YCBD
|
7.49 M | $ 0.7 | -0.19 % | $ 3.02 M | USA |
 |
Zomedica Corp.
ZOM
|
10.4 M | - | -0.21 % | $ 98 M | USA |
 |
Rockwell Medical
RMTI
|
57.6 M | $ 0.94 | -1.12 % | $ 33.8 M | USA |
 |
China Pharma Holdings
CPHI
|
4.28 M | $ 0.62 | 1.57 % | $ 2.66 M |  China |
 |
TherapeuticsMD
TXMD
|
1.4 M | $ 2.05 | 1.49 % | $ 23.7 M | USA |